Gastroenterology Research and Practice / 2016 / Article / Tab 2

Research Article

Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience

Table 2

Clinical characteristics of hepatocellular carcinoma (HCC) patients.

Mean ± SD(, %)

Tumor size (cm)5.7 + 5.1
Number of tumors
 Single 117(49.80%)
 Two lesions 33(14.00%)
 Multiple (≥3)85(36.20%)
Child-Turcotte-Pugh score
 A 135(57.40%)
Portal vein thrombosis 36(15.30%)
Vascular invasion 28(11.90%)
Metastasis 31(13.20%)
Noncirrhotic liver 44(18.70%)
Liver transplant21(8.9%)
MELD11 + 5
Bilirubin, μmol/L 41.5 ± 113
Albumin, g/L 34 ± 7
AST, U/L 96 ± 103
ALT, U/L64 ± 59
INR1.2 ± 0.4
AFP10934.2 ± 48
Platelets, ×109/L 201 ± 135
BCLC stages
Stage 0 (very early)8(3.4%)
Stage A (early)79(33.6%)
Stage B (intermediate)81(34.5%)
Stage C (advanced)42(17.9%)
Stage D (terminal)25(10.6%)

SD: standard deviation; MELD: model for end-stage liver disease; AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; INR: international normalized ratio; BCLC: Barcelona Clinic Liver Cancer.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.